Please assess the completion status of the following clinical trial:

Trial Title: Insulin Glulisine in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetes Mellitus, Type 2~* 25 \< BMI \< 45 kg/m²~* 7,5% \< HbA1c \< 9%~* Treated with a basal insulin (NPH, Insulin Zinc, Insulin glargine or Insulin detemir), and at least 1g metformin daily, for more than 3 months~Exclusion Criteria:~* Type 1 diabetes mellitus~* Treatment with OADs only~* Treatment with thiazolidinediones, with exenatide or with pramlintide~* Treatment with an insulin other than basal insulin (Premix, rapid insulin, fast-acting insulin analogue)~* Active proliferative diabetic retinopathy,~* Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and effective contraception)~* Breast-feeding~* History of hypersensitivity to the study drugs or to drugs with a similar chemical structure.~* Treatment with systemic corticosteroids in the 3 months prior to study entry~* Treatment with any investigational product in the 2 months prior to study entry~* Previous treatment with insulin glulisine~* Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol~* Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult~* Impaired hepatic function~* Impaired renal function~* History of drug or alcohol abuse~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- insulin glulisine+insulin glargine+metformin+glimepiride (Type: OTHER): Bolus arm
- insulin glargine+metformin+glimepiride (Type: OTHER): Control arm

Based on this trial design, predict the completion outcome and termination type (if applicable).